Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at lowering the cost of introducing innovative compounds to the market.

The areas of our activity include:

• target-based solutions – advanced protein modelling solutions
• drug discovery – custom in silico library construction
• lead generation – optimization of lead compounds
• contract synthesis and syntheses paths optimization
• information technology for research projects

Selvita develops its own innovative drugs, which originate from research at Polish universities and later out-licenses them to the customers from the pharmaceutical industry. Selvita is involved in the research projects up to the pre-clinical stage. Our current projects are in the area of oncology, central nervous system, infections and diagnostics. In future we will also be involved in projects in other therapeutic areas. Projects currently available for partnering:

SEL73 program

SEL73 is an aromatic, heterocyclic compound, acting on the serotonin/dopamine system. SEL73 has been invented as an atypical antipsychotic, and shows a high affinity towards serotonin 5-HT2a receptor, dopamine D2 receptor, has well as serotonin 5-HT7 receptor, and weak affinity towards serotonin 5-HT 1a receptor as measured in vitro.
This compound can be further developed in the field of schizophrenia (with or without bipolar mania), but also psychotic episodes of dementia with Lewy bodies and other psychotic disorders. Its function via 5-HT2a and D2 receptors was visible in behavioral tests in animals where it performed better than Clozapine or Haloperidol. 

SEL92 program

SEL92 is a novel, patented  new chemical entity presenting hypotensive activity.  SEL92 has been shown safe, not showing neither neurotoxicity or cardiotoxicity, when  tested in vivo.  It has a well-defined mechanism of action and good specificity as observed in functional ex-vivo and in vivo assays.
SEL92 can be further developed in the field of hypertensive disorders including  pregnancy-induced hypertension (pre-eclampsia), pulmonary hypertension as well as renovascular hypertension.

Selvita is also the owner of BioCentrum (www.biocentrum.com.pl), which provides preclinical ADMET services, biochemistry services with special focus on protein engineering and antibody development. We are also one of two partners in Gencron jv. Gencron is a service offering covering the optimum match of genetically identified patient groups to oncology drugs, which are currently under clinical and pre-clinical development (so called drug targeting) but also drugs which failed to achieve the expected milestones during their development cycle (drug repositioning).

Read more: Selvita Your Research Partner